In most people, the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) trigger mild cold-like symptoms. But in infants and seniors, these viruses can ...

In most people, the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) trigger mild cold-like symptoms. But in infants and seniors, these viruses can ...

The complex shape of respiratory syncytial virus is one hurdle limiting the development of treatments for an infection that leads to hospitalization or worse for hundreds of thousands of people in the ...

Researchers found that RSV protein subunit vaccines probably reduce RSV-related hospitalization (vaccine efficacy, 83.3%) and severe RSV illness (vaccine efficacy, 94.1%) in older adults. HealthDay ...

About The Study: In adults age 60 or older, all-cause cardiorespiratory hospitalization was significantly lower with respiratory syncytial virus (RSV) prefusion F protein than with no vaccine. The ...

As cold and flu season ramps up, the most vulnerable among us need extra protection. Infants are among the most susceptible to respiratory complications from respiratory syncytial virus, or RSV. While ...

Add Yahoo as a preferred source to see more of our stories on Google. Most RSV jab side effects are mild and don't last ling. (Getty Images) With the NHS kicking off its rollout of the Respiratory ...

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (ENTA) (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and ...

A novel vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, protected cattle from respiratory syncytial ...

RSV F proteins, shown in this image created by University of Wisconsin–Madison researchers using a technique called cryo-electron tomography, may make RSV more potent by keeping it from infecting ...